Haploidentical stem cell transplant for blood diseases
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study is a registry that tracks outcomes for adults with blood diseases (such as leukemia, lymphoma, or severe aplastic anemia) who receive a haploidentical stem cell transplant—a transplant from a half-matched donor. The goal is to gather real-world data to understand how well this approach works for people who do not have a fully matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood disease like acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, lymphoma, or severe aplastic anemia.
- You do not have a matched sibling or unrelated donor, and other treatments have been ruled out.
- You are older than 18 years.
- You are in reasonably good health (able to do daily activities, with adequate liver, kidney, and heart function).
- You do not have HIV, active hepatitis B or C, an active infection, or a history of other cancer (except certain skin or cervical cancers).
- If you are able to become pregnant, you must have a negative pregnancy test and agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.